Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05864742
Title Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (+/-Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS

Facility Status City State Zip Country Details
Princess Alexandra Hospital Woolloongabba Queensland 4102 Australia Details
Flinders Medical Centre Bedford Park South Australia 5042 Australia Details
Peter MacCallum Cancer Centre Parkville Victoria 3000 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field